CCT6A and neoplasm: Notably, both the tumor growth curve and final tumor weight measurements demonstrated that the anti-CD47 nanobody achieved a more effective therapeutic outcome in tumors with CCT6A knockdown, compared to the scramble control group (Fig. 7B–D).